



Intelligence Quotient in Paediatric Sickle Cell Disease: a Systematic Review and Meta-Analysis

Journal:	<i>Developmental Medicine & Child Neurology</i>
Manuscript ID:	DMCN-SRE-15-08-0490
Manuscript Type:	Systematic Review
Date Submitted by the Author:	06-Aug-2015
Complete List of Authors:	Kawadler, Jamie; UCL Institute of Child Health, Developmental Imaging & Biophysics Section Clark, Chris; UCL Institute of Child Health, Developmental Imaging & Biophysics Section Kirkham, Fenella; UCL Institute of Child Health, Clinical Neurosciences Section
Keywords:	sickle cell, intelligence, IQ, anemia, cognition

SCHOLARONE™
Manuscripts

Only

1
2 **Intelligence Quotient in Paediatric Sickle Cell Disease: a Systematic Review and Meta-**
3 **Analysis**
4

5
6 Jamie M. Kawadler¹, Chris A. Clark¹ & Fenella J. Kirkham²
7

8
9 ¹Developmental Imaging & Biophysics Section, Institute of Child Health, University College
10 London, UK
11

12 ²Clinical Neurosciences Section, Institute of Child Health, University College London, UK
13
14

15
16 Corresponding author:
17

18 Dr Jamie Kawadler
19 Developmental Imaging & Biophysics Section
20 UCL Institute of Child Health
21 30 Guilford Street
22 London WC1N 1EH
23 United Kingdom
24 Tel: +44 (0)207 905 2744
25 Fax: +44 (0)207 905 2358
26 Email: jamie.kawadler.11@ucl.ac.uk
27
28
29

30 Word Count: 2950
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Aim: Sickle cell disease (SCD) is the commonest cause of childhood stroke world-wide. Magnetic resonance imaging (MRI) is routinely used to detect additional silent cerebral infarction (SCI), as intelligence quotient (IQ) is lower in SCI as well as stroke. This review assesses the effect of infarction on IQ, and specifically whether, compared to healthy controls, IQ differences are seen in SCD children with no apparent MRI abnormality.

Method: A systematic review was conducted to include articles with a SCD paediatric population, MRI information and Wechsler IQ. A meta-analysis of nineteen articles was performed to compare IQ in three groups: Stroke vs. SCI, SCI vs. no SCI, and no SCI vs. healthy controls.

Results: Mean differences in IQ between all three groups were significant: Stroke patients had lower IQ than SCI patients by 10 points (6 studies), SCI patients had lower IQ than no SCI patients by 6 points (17 studies), and no SCI patients had lower IQ than healthy controls by 7 points (7 studies).

Interpretation: Children with SCD and no apparent MRI abnormality have significantly lower IQ than healthy controls. In this chronic condition, other biological, socioeconomic and environmental factors must play a significant role in cognition.

What this paper adds:

- Systematic review including recent IQ studies in SCD
- Meta-analysis including previously underreported results comparing SCD and healthy children
- Critical appraisal of SCI lesion size quantification studies
- Critical appraisal of appropriate control comparison group
- Discussion of non-radiological factors associated with lowered IQ

Running foot: IQ in Sickle Cell Disease

Introduction

Sickle cell disease (SCD) is a lifelong inherited genetic disease associated with a high prevalence of stroke and cognitive dysfunction in childhood. Approximately 10% of patients will experience an overt stroke¹; however, in the first decade of life around one third of children with SCD will accumulate at least one silent cerebral infarct (SCI; *i.e.* an abnormality seen on T2-weighted MRI in the absence of overt stroke, or neurological symptoms lasting more than 24 hours)². By definition, SCI are clinically silent and therefore age at which SCI occurred and time lapse between SCI and cognitive testing are unknown. Stroke and SCI have been associated with general cognitive dysfunction, including problems with sustained attention, cognitive flexibility and working memory³⁻⁷.

Full-scale intelligence quotient (IQ) is the most commonly reported and widely studied standardised measure of general cognitive ability in SCD. Chodokoff & Whitten (1963) published the first study investigating IQ between patients with SCD and controls – finding no differences; however from the 1980s/early 1990s there were many studies suggesting that patients have lowered global intelligence scores than matched controls, even when excluding those with history of stroke or abnormal neurological examination⁸⁻¹³. The first study that used magnetic resonance imaging (MRI) to classify patients into groups based on whether SCI are present or absent was published in 1996¹⁴; collaborators in the large Cooperative Study in Sickle Cell Disease (CSSCD) study in the United States linked presence of MRI abnormality and measurable global cognitive dysfunction. Since then, several studies have confirmed that children with SCI (SCI+) generally have lower IQ scores than those without evidence of SCI (SCI-)¹⁵⁻²⁰. These findings established a potential link between presence of lesions and lesion size as a mediating factor in a child's IQ score.

The presence, nature and aetiology of any differences in IQ between children with SCD without SCI (*i.e.* normal MRI) and healthy controls have however, received less attention. These studies are necessary to elucidate differences in neurocognitive outcome that may be due to subtle aspects of the disease other than presence of SCI, such as chronic anaemia and hypoxia²¹ and school absences, and to attempt to separate them from socioeconomic²² and environmental effects.

The purpose of this article is to evaluate the relationship between IQ and MRI status in children with SCD, through systematic review and a meta-analysis of published studies. A meta-analysis in 2002²³ found an overall difference of 4.3 standard IQ score points lower in children with SCD compared to controls, with a significant effect size. This review expands to separate the patient group by radiological status as seen on MRI (*i.e.* SCI+, SCI-), with a specific aim to answer the question of whether IQ differences are seen in children with no apparent MRI abnormality compared to healthy controls.

Methods

Literature searches were conducted on PubMed using the search terms “sickle cell” paired with either “intelligence” or “IQ” from 1980-2015. To be eligible for review, the peer-reviewed article must have been a cross-sectional design, included a paediatric SCD population, used MRI to define presence of absence of SCI and/or stroke, and used a Wechsler intelligence scale measure that reported IQ (*e.g.* WPPSI, WASI, WISC, WAIS). Systematic and other reviews were excluded, although references from those articles may have identified additional original articles. Additional articles that met inclusion criterion were also drawn from the references of each original article identified.

Seventy-three publications were identified through the literature search. From the aforementioned criteria, the following articles were excluded: 5 reviews and 1 letter to the editor, 3 articles with non-paediatric SCD populations, 28 articles without MRI information, and 6 articles without Wechsler scales. Additionally, 8 articles were excluded because the authors did not report IQ values or did not clearly state scores by MRI group, 1 article was excluded because of longitudinal design, 1 article with two groups was excluded due to only having one subject in one of the groups, and 1 article was excluded because patients only included those with HbA + SB₀ thalassaemia. Nineteen articles were included in this review (see Figure 1 for flow chart). For each article, participant age and mean IQ and standard deviation were recorded for each MRI group (Table 1).

Critical appraisal

FSIQ was not the primary outcome measure of many of these articles; however, to assess quality for this review, the articles were evaluated for characteristics that may affect FSIQ; criteria included details of how the groups were identified (*i.e.* SCI identification on MRI), lesion size assessment (if applicable) and appropriateness of control group (*i.e.* sibling/community control, data from normative databases).

Statistical analysis

Each study analysed reported Wechsler full-scale IQ scaled for developmental stage with mean 100, standard deviation 15 and range 40-160. A meta-analysis was performed using the metafor²⁴ package in R (www.r-project.org). Three group comparisons were analysed: 1) mean difference between Stroke and SCI+ groups (n=6 studies), 2) mean difference between SCI+ and SCI- groups (17 studies), and 3) mean difference between SCI- and healthy controls (HC; n=7 studies).

The 19 studies were drawn from different countries and were assumed to each contain a sample of the SCD population. The data was assumed to be heterogeneous (*i.e.* not every study showing the same true effect size in differences in mean IQ); therefore a random-effects restricted maximum-likelihood estimator model, which estimates heterogeneity, was fitted to the data for each group comparison. Estimates and 95% confidence intervals of between-group mean differences were calculated and displayed on forest plots.

Results

Of the 19 studies included in this review, 6 included a Stroke group, 17 included a SCI+ group, and 7 included a HC group. Mean IQ ranged between 65.9 to 76.9 in the Stroke group, between 70.6 to 93.12 in the SCI+ group, between 78.9 to 103.12 in the SCI- group, and between 88 to 108.29 in the HC group (Table 1).

Critical appraisal

As presence of SCI has been shown to affect IQ, this study aimed to critically appraise how SCI are identified in these studies and how lesion size estimation was performed. Additionally, fewer studies employed a control group for comparison, and characteristics of these control groups were critiqued.

Identification and measurement of SCI

Definitions of SCI varied; most studies defined SCI as an area of abnormally increased signal intensity on T2-weighted or FLAIR sequences, without history of a focal neurological

1 event^{14,17,19,25-28}. Some, however, defined patient groups by normal or 'abnormal' MRI, which may
2 have included different aetiologies including lacunar infarction, leukoencephalopathy and
3 encephalomalacia^{15,18}. Other studies included MR angiography to discern major vessel watershed
4 infarction from unilateral and bilateral high-signal lesions¹⁶. More recently, several US studies
5 defined SCI as an MRI signal abnormality at least 3mm in one direction and visible on two views
6 on FLAIR T2-weighted images^{22,29,30}, as used in the Silent Infarct Transfusion trial³¹.

7
8
9
10 Ten of 17 studies that included an SCI group did not describe any lesion size measurement for
11 analysis, and three studies used a qualitative measurement (*i.e.* categorizing lesions into focal/small
12 <0.5cm, medium 0.5-1.5cm, or large >1.5cm)^{3,14,26}. The remaining four studies quantified lesion
13 size as a continuous variable, either by manual tracing of hyperintense voxels and converting to
14 mm³ by multiplying by slice thickness and gap^{29,30}, manual tracing of T2-weighted images that have
15 been registered to Montreal Neurologic Institute (MNI) space¹⁹, or using a semi-automatic method
16 and multiplying segmented voxels by voxel volume²⁸. The effect of lesion quantification method on
17 results are mixed; one study did not provide any correlation result with IQ¹⁹, two studies found
18 volume of SCI to be a significant predictor of IQ^{28,29} and one study found only patients with larger
19 lesions had lower IQ³⁰.

21 *Studies with healthy control group*

22 Seven studies included a healthy control group. However, 'control group' consisted of different
23 characteristics depending on the study: group of siblings recruited contemporaneously with
24 patients^{3,16,32}, group of siblings as well as non-ethnically matched control subjects recruited
25 contemporaneously with patients¹⁹, group of community controls matched for age, gender, race and
26 socioeconomic status recruited contemporaneously with patients²⁹, group of historical sibling data
27 (not siblings of the patients recruited)¹⁵ and group of normative data from the WISC matched for
28 age, race and gender³³.

29
30
31 The use of varied control groups gave mixed results when comparing with SCD patients with
32 normal MRI. Two studies that included siblings as a comparison group found 5-³² and 6-point³ IQ
33 reductions in patients, but results were non-significant, while one study did not specifically test
34 those groups¹⁶. One study found SCI- patients had significantly lower IQ than controls, when the
35 controls consisted of siblings and non-ethnically matched subjects¹⁹. No differences were found
36 between SCI- patients and a sample of community controls²⁹. When using historical sibling data¹⁵
37 or normative database data³³, SCI- patients scored significantly lower than the control comparison
38 group.

41 *Meta-analysis*

42
43
44 The random-effects model estimated the amount of total heterogeneity (τ^2) and performed
45 Cochran's *Q*-test for heterogeneity³⁴. There was significant heterogeneity in the Stroke vs. SCI+
46 comparison, while non-significant heterogeneity in the SCI+ vs. SCI- and SCI- vs. HC
47 comparisons; however, the random-effects model was used for consistency (Table 2).

48
49
50 Mean differences in IQ between Stroke vs SCI+, SCI+ vs SCI- and SCI- vs HC groups were all
51 significant (Table 2, Figure 2). For the Stroke vs SCI+ analysis, the model estimated stroke groups
52 have a mean difference of 10.31 IQ points lower than SCI+ groups ($p=0.0013$). For the SCI+ vs
53 SCI- analysis, the model estimated the SCI+ groups have a mean difference of 5.83 IQ points lower
54 than SCI- groups ($p<0.0001$). For the SCI- vs HC analysis, the model estimated SCI- groups have a
55 mean difference of 6.90 IQ points lower than healthy control groups ($p<0.0001$).

Discussion

IQ, a representative of a child's general cognitive ability, has been widely used in the SCD literature for more than 30 years. Many studies have established a trend for decreasing IQ with MRI status using age-appropriate Wechsler scales for children; this review analysed all studies that reported IQ by MRI status, to elucidate differences between those studies that grouped SCD patients together regardless of MRI abnormality.

The results of the meta-analysis of 19 studies confirm this trend for decreased IQ: patients with history of stroke perform significantly worse than those with SCI by approximately 10 IQ points and children with SCI perform significantly worse than children without SCI (normal MRI) by approximately 6 IQ points. This meta-analysis also finds children with normal MRI perform significantly worse than healthy controls by approximately 7 IQ points. This is in contrast to some previous conclusions²⁸; these findings suggest that presence of lesions, or lesion size alone, may not account for all differences in IQ in children with SCD. Other factors, whether biologic²², socioeconomic²² or environmental³⁵, are likely to play an additional role in the child's cognitive outcome.

Effect of SCI on FSIQ

Presence of SCI

SCI have been reported to occur in at least 27% of children with SCD before 6 years of life³⁶, and the number and size of lesions have been shown to increase over time in children with SCI who do not develop clinical stroke³⁷. SCI in children with SCD are considered to be secondary to small vessel disease, mainly affecting the white matter in the frontal lobe borderzones between the anterior and middle cerebral artery territories³⁸, but may also result from acute events, including posterior reversible encephalopathy syndrome³⁹ and fall in haemoglobin⁴⁰. Results from a previous meta-analysis published 13 years ago found that children with evidence of SCI on MRI have IQ scores approximately 4-7 points lower than children without evidence of SCI²³, which is in line with the approximate 6 point reduction found between those two groups found in this meta-analysis.

Size of SCI

Previous reports have shown presence of SCI or lesion volume as an independent predictor of FSIQ^{22,28,29}. However, there may be a threshold of lesion size before IQ is affected; in one study, small infarct volume appeared to have minimal impact on global cognitive ability but larger volume was associated with lowered FSIQ scores in eight patients with SCI⁵⁰. It is of note that these articles showed discrepancies in lesion quantification methods. Quantitative lesion measurements from T2-weighted or FLAIR images were 2D sequences with 3mm or 5mm thick slices, sometimes with 2-3mm gaps between slices; a 3D sequence with isotropic voxel sizes would have been ideal to rule out potential partial volume effects.

Neuroimaging correlates of FSIQ

Quantitative neuroimaging has shown neuroanatomical correlates of decreased IQ in children with SCD. White matter density, as determined by voxel-based morphometry, was found to correlate with verbal IQ in the left hemisphere, as well as performance IQ in the right hemisphere, but not full-scale IQ¹⁹. Two studies^{41,42} were excluded from this review because the authors did not report FSIQ scores by MRI group; however, these authors found neuroimaging correlates of FSIQ of note. Steen and colleagues⁴¹ found an inverse relationship between basilar artery volume and FSIQ ($r=-$

0.62, $p < 0.005$), while Strouse and colleagues⁴² found an inverse correlation between right-hemisphere cerebral blood flow and FSIQ ($p = 0.04$) and performance IQ ($p = 0.01$).

Biological determinants of FSIQ

Previous studies have shown SCD-related markers of disease severity to correlate with intelligence, which may explain differences in IQ between patients with normal MRI and healthy controls. There have been links with anaemia severity^{16,18,43-45}; more specifically, haematocrit^{16,43} and the interaction between age and haematocrit²⁶, that have also been shown in non-SCD populations⁴⁶⁻⁴⁸. This correlation between anaemia and IQ could be due to a direct impact on the brain (*i.e.* anaemia-induced hypoxia/ischaemia) or due to indirect influences on processes such as the body's response to anaemic hypoxia exposure⁴¹, which leads to increased cerebral blood flow⁴⁹⁻⁵¹ and cerebral blood flow velocity^{52,53} reduction in cerebrovascular reserve⁵⁴ and subsequent large and small vessel injury/ischaemia⁵⁵. In a model for explanatory factors of IQ, each 1% decrease in haemoglobin oxygen saturation was found to be associated with 0.75 IQ point decrease²². Chronically altered cerebral circulation may lead to a cycle of long-term hypoxia⁴³ and cognitive dysfunction⁵⁶. Three studies included in this review find a negative association between chronologic age and FSIQ in cross-sectional study design^{18,22,26}, while a longitudinal study from the CSSCD showed on average, FSIQ decreased 1.2 point per year with age⁵⁷. Other SCD-related biomarkers previously linked to cognitive outcome include growth delays^{11,58,59}, possibly linked to poor nutrition¹¹, that may have an effect on the development and maturation of the brain^{29,60}, but relatively few studies have included height as a predictor of IQ in SCD, despite the importance of this measure in the general population⁶¹.

Environmental determinants of FSIQ

SCD has been called a neurodevelopmental disorder, in which both biological and social factors impact cognitive functioning^{44,62}. Like other chronic diseases, and in addition to chronic intermittent pain⁶³, SCD is associated with frequent hospitalisations^{64,65} for a variety of complications including acute hypoxia due to chest crisis and acute anaemia (aplastic and sequestration), which have been shown to affect cognitive functioning⁶⁶. The home environment with a child with SCD can be especially stressful for both the child⁶⁷⁻⁶⁹ and caregiver⁷⁰. In an academic setting, children with SCD have been shown to demonstrate deficits in reading, writing, arithmetic and spelling compared to healthy peers and siblings^{8,10,12,14,17,23,71}; this limited academic achievement⁷² is likely due to high proportions of illness, school absenteeism and grade retention⁷³. Poverty³⁵/low socioeconomic status^{74,75} and lack of parent education²² are commonly found in SCD, and have been associated with lower IQ scores²². Living in cities may expose already vulnerable children to pollutants known to affect risk of cerebral infarction and to unfavourably alter brain structure in adults⁷⁶. Lead exposure may have affected children born before 1985⁷⁷, when few studies included sibling controls, and might still have a differential effect on children with a chronic condition making them vulnerable to brain damage⁷⁸. Noise pollution from aircraft and traffic may also play a role⁷⁹.

Use of appropriate control groups

An appropriate control group should be identical to the patient study group, with the exception of the specific variable under investigation. Siblings (recruited contemporaneously with patients) constitute the most appropriate comparison group, as many environmental factors attributing to cognition (*i.e.* socioeconomic status, parental education, ethnic background) are controlled^{17,80}. Normative data from standardised Wechsler scales do not constitute a fair comparison^{18,80}, and one can argue community controls, while perhaps matched for ethnic background and socioeconomic

1 status, do not share the characteristics of the home environment of a child with SCD. This review
2 critically analysed the composition of the control comparison groups for studies investigating IQ in
3 SCD. Of all the studies included in this review, only two studies recruited only siblings
4 contemporaneously with SCD patients; both found lower, but non-significant IQ scores in SCI-
5 patients^{3,32}. We recommend careful consideration when interpreting results of studies with
6 inappropriate control comparison groups.
7
8

9 *Limitations*

10 While the Wechsler scales are a reliable measure of general cognitive ability, some argue that they
11 fail to relate to real-world performance⁸¹. Along with school difficulties, children can also be
12 impaired in age-appropriate life tasks, such as chores and cultural activities⁸². Cognitive impairment
13 continues into adulthood⁸³, and effective education and social interventions to improve academic
14 attainment/achievement and quality of life are necessary to ensure productivity and vocational
15 success.
16
17

18 It is possible some of the studies used overlapping participants in reporting IQ. Five studies
19 included multicentre^{14,17} and single-centre^{15,33} data from CSSCD, and one study²⁵ included data
20 from participants enrolled in both CSSCD and Stroke Prevention in Sickle Cell Anaemia (STOP)
21 trials.
22
23

24 In summary, this systematic review and meta-analysis confirms a step-wise progression of declining
25 IQ corresponding to presence of SCI and clinical stroke, but also significantly lowered IQ between
26 children with SCD with no evidence of MRI abnormality and healthy controls. While presence of
27 SCI affects cognitive outcome in children with SCD, it is likely that biological, socioeconomic and
28 environmental factors play an important role in intellectual functioning.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**denotes articles included in meta-analysis*

References

1. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. *Blood*. 1998 Jan 1;91(1):288–94.
2. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. *Blood*. 2012 May 17;119(20):4587–96.
- *3. Watkins KE, Hewes DK, Connelly A, Kendall BE, Kingsley DP, Evans JE, et al. Cognitive deficits associated with frontal-lobe infarction in children with sickle cell disease. *Dev Med Child Neurol*. 1998 Aug;40(8):536–43.
4. DeBaun MR, Schatz J, Siegel MJ, Koby M, Craft S, Resar L, et al. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. *Neurology*. 1998 Jun;50(6):1678–82.
- *5. Brown RT, Davis PC, Lambert R, Hsu L, Hopkins K, Eckman J. Neurocognitive functioning and magnetic resonance imaging in children with sickle cell disease. *J Pediatr Psychol*. 2000;25(7):503–13.
6. Schatz J, Brown RT, Pascual JM, Hsu L, Debaun MR. Poor school performance and cognitive functioning with silent cerebral infarcts and sickle cell disease. *Neurology*. 2001;56:1109–11.
7. Christ SE, Moinuddin A, McKinstry RC, DeBaun M, White DA. Inhibitory control in children with frontal infarcts related to sickle cell disease. *Child Neuropsychol*. 2007 Mar;13(2):132–41.
8. Swift A V, Cohen MJ, Hynd GW, Wisenbaker JM, McKie KM, Makari G, et al. Neuropsychologic impairment in children with sickle cell anemia. *Pediatrics*. 1989 Dec;84(6):1077–85.
9. Hariman LM, Griffith ER, Hurtig AL, Keehn MT. Functional outcomes of children with sickle-cell disease affected by stroke. *Arch Phys Med Rehabil*. 1991 Jun;72(7):498–502.
10. Wasserman ALL, Wilimas JAA, Fairclough DLL, Mulhern RKK, Wang W. Subtle neuropsychological deficits in children with sickle cell disease. *Am J Pediatr Hematol Oncol*. 1991;13(1):14–20.
11. Knight S, Singhal A, Thomas P, Serjeant G. Factors associated with lowered intelligence in homozygous sickle cell disease. *Arch Dis Child*. 1995;73(4):316–20.
12. Noll RB, Stith L, Gartstein M a, Ris MD, Grueneich R, Vannatta K, et al. Neuropsychological functioning of youths with sickle cell disease: comparison with non-chronically ill peers. *J Pediatr Psychol*. 2001 Mar;26(2):69–78.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13. Hijmans CT, Fijnvandraat K, Grootenhuis MA, van Geloven N, Heijboer H, Peters M, et al. Neurocognitive deficits in children with sickle cell disease: a comprehensive profile. *Pediatr Blood Cancer*. 2011 May;56(5):783–8.
- *14. Armstrong FD, Thompson RJ, Wang W, Zimmerman R, Pegelow H, Miller S, et al. Cognitive Functioning and Brain Magnetic Resonance Imaging in Children With Sickle Cell Disease. *Pediatrics*. 1996;97(6):864–70.
- *15. Steen RG, Reddick WE, Mulhern RK, Langston JW, Ogg RJ, Bieberich AA, et al. Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI. *J Magn Reson Imaging*. 1998;8(3):535–43.
- *16. Bernaudin F, Verlhac S, Freard F, Roudot-Thoraval F, Benkerrou M, Thuret I, et al. Multicenter Prospective Study of Children With Sickle Cell Disease: Radiographic and Psychometric Correlation. *J Child Neurol*. 2000 May 1;15(5):333–43.
- *17. Wang W, Enos L, Gallagher D, Thompson R, Guarini L, Vichinsky E, et al. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. *J Pediatr*. 2001 Sep;139(3):391–7.
- *18. Steen RG, Miles M a, Helton KJ, Strawn S, Wang W, Xiong X, et al. Cognitive impairment in children with hemoglobin SS sickle cell disease: relationship to MR imaging findings and hematocrit. *AJNR Am J Neuroradiol*. 2003 Mar;24(3):382–9.
- *19. Baldeweg T, Hogan AM, Saunders DE, Telfer P, Gadian DG, Vargha-Khadem F, et al. Detecting white matter injury in sickle cell disease using voxel-based morphometry. *Ann Neurol*. 2006 Apr;59(4):662–72.
20. Scantlebury N, Mabbott D, Janzen L, Rockel C, Widjaja E, Jones G, et al. White matter integrity and core cognitive function in children diagnosed with sickle cell disease. *J Pediatr Hematol Oncol*. 2011 Apr;33(3):163–71.
21. Armstrong FD. Neurocognitive function in sickle cell disease: have we been missing something? *Expert Rev Hematol*. 2010 Oct;3(5):519–21.
- *22. King AA, Strouse JJ, Rodeghier MJ, Compas BE, Casella JF, McKinsty RC, et al. Parent education and biologic factors influence on cognition in sickle cell anemia. *Am J Hematol*. 2014 Feb;89(2):162–7.
23. Schatz J, Finke RL, Kellett JM, Kramer JH. Cognitive functioning in children with sickle cell disease: a meta-analysis. *J Pediatr Psychol*. 2002 Dec;27(8):739–48.
24. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw*. 2010;36(3):1–48.
- *25. Wang WC, Gallagher DM, Pegelow CH, Wright EC, Vichinsky EP, Abboud MR, et al. Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. *J Pediatr Hematol Oncol*. 2000 Jan;22(4):335–9.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- *26. Kral MC, Brown RT, Connelly M, Curé JK, Besenski N, Jackson SM, et al. Radiographic Predictors of Neurocognitive Functioning in Pediatric Sickle Cell Disease. *J Child Neurol.* 2006;21(1):37–44.
 - *27. White DA, Moinuddin A, McKinstry RC, Noetzel M, Armstrong M, DeBaun M. Cognitive screening for silent cerebral infarction in children with sickle cell disease. *J Pediatr Hematol Oncol.* 2006 Mar;28(3):166–9.
 - *28. Van der Land V, Hijmans CT, de Ruiter M, Mutsaerts HJMM, Cnossen MH, Engelen M, et al. Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in children with sickle cell disease. *Br J Haematol.* 2015 Oct 10;168:553–6.
 - *29. Schatz J, Buzan R. Decreased corpus callosum size in sickle cell disease: relationship with cerebral infarcts and cognitive functioning. *J Int Neuropsychol Soc.* 2006 Jan;12(1):24–33.
 - *30. Schatz J, White DA, Moinuddin A, Armstrong M, DeBaun MR. Lesion burden and cognitive morbidity in children with sickle cell disease. *J Child Neurol.* 2002 Dec;17(12):891–5.
 - 31. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White D a, Sarnaik S a, et al. Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia. *N Engl J Med.* 2014 Aug 21;371(8):699–710.
 - *32. Kawadler JM, Kirkham FJ, Clayden JD, Hollocks MJ, Seymour EL, Edey R, et al. White Matter Damage Relates to Oxygen Saturation in Children With Sickle Cell Anemia Without Silent Cerebral Infarcts. *Stroke.* 2015;1793–800.
 - *33. Steen RG, Fineberg-Buchner C, Hankins G, Weiss L, Prifitera A, Mulhern RK. Cognitive Deficits in Children With Sickle Cell Disease. *J Child Neurol.* 2005 Feb 1;20(2):102–7.
 - 34. Cochran WG. The combination of estimates from different experiments. *Biometrics.* 1954;10:101–29.
 - 35. King A, Rodeghier M, Panepinto J, Strouse J, Casella J, Quinn C, et al. Silent Cerebral Infarction, Income and Grade Retention among Students with Sickle Cell. *Am J Hematol.* 2014;2–28.
 - 36. Kwiatkowski JL, Zimmerman R a, Pollock AN, Seto W, Smith-Whitley K, Shults J, et al. Silent infarcts in young children with sickle cell disease. *Br J Haematol.* 2009 Aug;146(3):300–5.
 - 37. Pegelow C, Reed G, Moser F, Al E. Natural history of silent infarcts in children with sickle cell anemia (HbSS), abstract. *Blood.* 1999;94:419A.
 - 38. Pegelow CH. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. *Blood.* 2002 Apr 15;99(8):3014–8.
 - 39. Henderson JN, Noetzel MJ, McKinstry RC, White DA, Armstrong M, DeBaun MR. Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease. *Blood.* 2003 Jan 15;101(2):415–9.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
40. Dowling MM, Quinn CT, Plumb P, Rogers ZR, Rollins NK, Koral K, et al. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. *Blood*. 2012 Nov 8;120(19):3891–7.
 41. Steen RG, Langston JW, Ogg RJ, Mancini E, Mulhern RK, Wang W. Ectasia of the basilar artery in children with sickle cell disease: relationship to hematocrit and psychometric measures. *J Stroke Cerebrovasc Dis*. 1998;7(1):32–43.
 42. Strouse JJ, Cox CS, Melhem ER, Lu H, Kraut M a, Razumovsky A, et al. Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemia (SCA). *Blood*. 2006 Jul 1;108(1):379–81.
 43. Steen RG, Xiong X, Mulhern RK, Langston JW, Wang WC. Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. *Ann Neurol*. 1999 Mar;45(3):279–86.
 44. Schatz J, Finke R, Roberts CW. Interactions of biomedical and environmental risk factors for cognitive development: a preliminary study of sickle cell disease. *J Dev Behav Pediatr*. 2004 Oct;25(5):303–10.
 - *45. Hijmans CT, Grootenhuis MA, Oosterlaan J, Peters M, Fijnvandraat K. Neurocognitive Deficits in Children With Sickle Cell Disease Are Associated With the Severity of Anemia. *Pediatr Blood Cancer*. 2011;(July 2010):297–302.
 46. Pollitt E. Iron deficiency and cognitive function. *Annu Rev Nutr*. 1993 Jan;13:521–37.
 47. Otero GA, Aguirre DM, Porcayo R, Fernández T. Psychological and electroencephalographic study in school children with iron deficiency. *Int J Neurosci*. 1999 Aug;99(1-4):113–21.
 48. Weiskopf RB, Feiner J, Hopf H, Lieberman J, Finlay HE, Quah C, et al. Fresh blood and aged stored blood are equally efficacious in immediately reversing anemia-induced brain oxygenation deficits in humans. *Anesthesiology*. 2006 May;104(5):911–20.
 49. Oguz KK, Golay X, Pizzini FB, Freer C a, Winrow N, Ichord R, et al. Sickle cell disease: continuous arterial spin-labeling perfusion MR imaging in children. *Radiology*. 2003 May;227(2):567–74.
 50. Gevers S, Nederveen AJ, Fijnvandraat K, van den Berg SM, van Ooij P, Heijtel DF, et al. Arterial spin labeling measurement of cerebral perfusion in children with sickle cell disease. *J Magn Reson Imaging*. 2011 Nov 16;35:119–787.
 51. Hales PW, Kawadler JM, Aylett SE, Kirkham FJ, Clark C a. Arterial spin labeling characterization of cerebral perfusion during normal maturation from late childhood into adulthood: normal “reference range” values and their use in clinical studies. *J Cereb blood flow Metab*. Nature Publishing Group; 2014 Feb 5;(October 2013):1–9.
 52. Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. Cerebral infarction in sickle cell anemia: Mechanism based on CT and MRI. *Neurology*. 1988 Jul 1;38(7):1012 – .

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
- *53. Hogan AMA, Cate I, Vargha-Khadem F, Prengler M, Kirkham FFJ, Pit-ten Cate IM, et al. Physiological correlates of intellectual function in children with sickle cell disease: hypoxaemia, hyperaemia and brain infarction. *Dev Sci.* 2006 Jul;9(4):379–87.
54. Prohovnik I, Pavlakis SG, Piomelli S, Bello J, Mohr JP, Hilal S, et al. Cerebral hyperemia, stroke, and transfusion in sickle cell disease. *Neurology.* 1989;39:344–8.
55. Prohovnik I, Hurllet-Jensen A, Adams R, De Vivo D, Pavlakis SG. Hemodynamic etiology of elevated flow velocity and stroke in sickle-cell disease. *J Cereb Blood Flow Metab.* 2009 Apr;29(4):803–10.
56. Kirkham FFJ, Datta AKA. Hypoxic adaptation during development: relation to pattern of neurological presentation and cognitive disability. *Dev Sci.* 2006;9(4):411–27.
57. Thompson RJ, Armstrong FD, Link CL, Pegelow CH, Moser F, Wang WC. A prospective study of the relationship over time of behavior problems, intellectual functioning, and family functioning in children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. *J Pediatr Psychol.* 2003;28(1):59–65.
58. Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. *N Engl J Med.* 1984 Jul 5;311(1):7–12.
59. Puffer ES, Schatz JC, Roberts CW. Association between somatic growth trajectory and cognitive functioning in young children with sickle cell disease. *J Health Psychol.* 2014 Dec 8;
60. Steen RG, Emudianughe T, Hunte M, Glass J, Wu S, Xiong X, et al. Brain volume in pediatric patients with sickle cell disease: Evidence of volumetric growth delay? *AJNR Am J Neuroradiol.* 2005 Mar;26(3):455–62.
61. Pearce MS, Deary IJ, Young AH, Parker L. Growth in early life and childhood IQ at age 11 years: the Newcastle Thousand Families Study. *Int J Epidemiol.* 2005 Jun;34(3):673–7.
62. Schatz J, McClellan CB. Sickle Cell Disease as a Neurodevelopmental Disorder. *Ment Retard Dev Disabil Res Rev.* 2006;12:200–7.
63. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. *Blood.* 2012 Aug 24;3647–56.
64. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. *JAMA.* 2010 Apr 7;303(13):1288–94.
65. McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. *Pediatr Blood Cancer.* 2013 May;60(5):823–7.
66. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. *Prog Neurobiol.* Elsevier Ltd; 2011 Mar;93(3):385–404.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
67. Gil KM, Carson JW, Porter LS, Ready J, Valrie C, Redding-lallinger R, et al. Daily Stress and Mood and Their Association With Pain , Health-Care Use , and School Activity in Adolescents With Sickle Cell Disease. 2001;(1998).
68. Frank N, Allison S, Cant M. Sickle Cell Disease. Cognitive Aspects of Chronic Illness in Children. New York: Guilford; 1999. p. 172–89.
69. Tarazi R a, Grant ML, Ely E, Barakat LP. Neuropsychological functioning in preschool-age children with sickle cell disease: the role of illness-related and psychosocial factors. Child Neuropsychol. 2007 Mar;13(2):155–72.
70. Moskowitz JT, Butensky E, Harmatz P, Vichinsky E, Heyman MB, Acree M, et al. Caregiving time in sickle cell disease: psychological effects in maternal caregivers. Pediatr Blood Cancer. 2007 Jan;48(1):64–71.
71. Fowler M, Whitt J, Lallinger R, Nash K, Atkinson S, Wells R, et al. Neuropsychologic and Academic Functioning of Children with Sickle Cell Anemia. Dev Behav Pediatr. 1988;9(4):213–20.
72. Fowler MG, Johnson MP, Atkinson SS. School achievement and absence in children with chronic health conditions. J Pediatr. 1985 Apr;106(4):683–7.
73. Epping A, Myrvik M. Academic Attainment Findings in Children With Sickle Cell Disease. J Sch Health. 2013;83(8).
74. Farber MD, Koshy M, Kinney TR. Cooperative Study of Sickle Cell Disease: Demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis. 1985 Jan;38(6):495–505.
75. Boulet SL, Yanni EA, Creary MS, Olney RS. Health status and healthcare use in a national sample of children with sickle cell disease. Am J Prev Med. 2010 Apr;38(4 Suppl):S528–35.
76. Wilker EH, Preis SR, Beiser AS, Wolf PA, Au R, Kloog I, et al. Long-term exposure to fine particulate matter, residential proximity to major roads and measures of brain structure. Stroke. 2015 May;46(5):1161–6.
77. Nevin R. How lead exposure relates to temporal changes in IQ, violent crime, and unwed pregnancy. Environ Res. 2000 May;83(1):1–22.
78. Brink LL, Talbott EO, Sharma RK, Marsh GM, Wu WC, Rager JR, et al. Do US ambient air lead levels have a significant impact on childhood blood lead levels: results of a national study. J Environ Public Health. 2013 Jan;2013:278042.
79. Clark C, Crombie R, Head J, van Kamp I, van Kempen E, Stansfeld SA. Does traffic-related air pollution explain associations of aircraft and road traffic noise exposure on children’s health and cognition? A secondary analysis of the United Kingdom sample from the RANCH project. Am J Epidemiol. 2012 Aug 15;176(4):327–37.
80. White D, DeBaun M. Cognitive and behavioral function in children with sickle cell disease: a review and discussion of methodological issues. J Pediatr Hematol Oncol. 1998;20(5):458–62.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
81. Burgess PW, Alderman N, Forbes C, Costello A, Coates LM, Dawson DR, et al. The case for the development and use of “ecologically valid” measures of executive function in experimental and clinical neuropsychology. *J Int Neuropsychol Soc.* 2006;12:194–209.
82. Patel AB, Pathan HG. Quality of life in children with sickle cell hemoglobinopathy. *Indian J Pediatr.* 2005 Jul;72(7):567–71.
83. Vichinsky E, Neumayr L, Gold J. Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Anemia. *JAMA.* 2010;303(18):1823–31.

For Review Only

Author(s)	Genotype	Stroke group (n)	SCI+ group (n)	SCI- group (n)	HC Group	Age (years)	Battery	Stroke FSIQ: mean (sd)	SCI+ FSIQ: mean (sd)	SCI- FSIQ: mean (sd)	HC FSIQ: mean (sd)
Armstrong et al. (1996)	HbSS/HbSC (n=194)	9	24	161	none	range: 6-12	WISC-R	70.8 (5)	82.8 (2.9)	90 (1.7)	-
Steen et al. (1998)	SCD (n=22)	-	10	12	30	patients = mean 10.5 ± 3.4, controls = mean 10.5 ± 3.0	WISC-R WISC-III	-	70.6 (12.1)	78.9 (8.9)	88 (16.1)
Watkins et al. (1998)	SCD (n=39)	5	4	30	15	range: 5.9-16.7	WISC-III WPPSI-R	67.6 (16.6)	79 (5.7)	86.03 (12)	92.07 (12.2)
Bernaudin et al. (2000)	SCD (n=173)	11	17	104	76	range: 5-15	WISC-III WPPSI-R	73.5 (14.4)	82.6 (15.7)	86.6 (17.1)	90.3 (14.3)
Brown et al. (2000)	HbSS/HbSC (n=63)	22	11	30	none		WISC-III	75.05 (15.53)	81.91 (14.43)	81.67 (16.68)	-
Wang et al. (2000)	HbSS/HbS β ⁰ -thalassaemia (n=73)	-	14	59	none	range: 6-16	WISC-III	-	73.0 (12.1)	86.0 (15.0)	-
Wang et al. (2001)	HbSS (n=185)	20	43	122	none	range: 6-12	WISC-R WISC-III	76.9 (17.2)	77.2 (13.7)	84.8 (13.5)	-
Schatz et al. (2002)	HbSS (n=27)	-	18	9	none	SCI+ patients = mean 12.4 ± 1.9, SCI- patients = mean 11.6 ± 3.0	WASI	-	81.9 (12.4)	89.9 (7.9)	-
Steen et al. (2003)	HbSS (n=49)	-	16	33	none	range: 4-19.7	WISC-R WISC-III	-	78.6 (16.1)	81.1 (11)	-
Steen et al. (2005)	HbSS (n=54)	-	-	30	30	10.9 ± 2.9	WISC-III	-	-	79.4 (11.9)	91.37 (12.19)
Baldeweg et al. (2006)	HbSS/HbSC (n=36)	-	16	20	31	SCI- patients = 17.1 ± 4.1, SCI+ patients = 18.2 ± 4.4, controls = 15.7 ± 3.6	WISC-III WAIS	-	82 (13)	92 (14)	101 (11)
Hogan et al. (2006)	SCD (n=30)	-	17	13	none	17.4 ± 4.2	WISC-III WAIS-R	-	82.5 (12.5)	87.4 (8.1)	-

Kral <i>et al.</i> (2006)	HbSS (n=27)	-	5	22	none		WASI	-	90.60 (3.05)	87.59 (11.42)	-
Schatz & Buzan (2006)	HbSS (n=28)	8	8	12	16		WISC-III	65.9 (14.8)	92.9 (12.8)	94.5 (14.2)	97.9 (11.8)
White <i>et al.</i>, (2006)	SCD (n=65)	-	16	49	none	8.0-16.9 years	WASI	-	85.8 (12.7)	90.0 (12.9)	-
Hijmans <i>et al.</i> (2011)	HbSS/HbS β-thalassaemia (n=34)	-	22	9	none	6-12 years	WISC-III WAIS-III	-	79 (14.4)	80 (9)	-
King <i>et al.</i> (2014)	HbSS/HbS β-thalassaemia (n=150)	-	107	43	none	5-15 years	WASI WPPSI-III	-	93.12 (12.5)	100.53 (13.08)	-
van der Land <i>et al.</i> (2015)	HbSS/HbS β ⁰ -thalassaemia (n=38)	-	19	19	none	8.2-17.1 years	WISC-III/WAIS-III	-	81 (7)	89 (12)	-
Kawadler <i>et al.</i> (2015)	HbSS (n=25)	-	-	25	14	8-18 years	WASI	-	-	103.12 (11.95)	108.29 (11.69)
WISC-R=Wechsler Intelligence Scale for Children – Revised (age 6 years, 0 months – 16 years, 11 months); WISC =Wechsler Intelligence Scale for Children (age 6 years, 0 months – 16 years, 11 months); WPPSI= Wechsler Preschool and Primary Scale of Intelligence (age 2 years, 6 months – 7 years, 3 months); WASI=Wechsler Abbreviated Scale of Intelligence (age 6-89 years); WAIS= Wechsler Adult Intelligence Scale (age 16 years, 0 months – 90 years, 11 months)											

Table 1. Overview of original articles included in meta-analysis.

	Stroke vs. SCI+ group	SCI+ vs. SCI- group	SCI- vs. HC group
Number of studies	6	17	7
Random-effects model			
Estimated total heterogeneity (τ^2)	35.11	4.49	2.37
Cochran's Q (p)	12.32 (p=0.03)	22.96 (p=0.11)	5.85 (p=0.44)
Model estimate (95% CI)	-10.31** (-16.58 - -4.04)	-5.83*** (-7.70 - -3.95)	-6.90*** (-9.74 - -4.07)
p<0.01, *p<0.001			

Table 2. Results of meta-analysis.

1
2 **Figure Legends**
3

4 **Figure 1.** Systematic review flow chart.
5

6 **Figure 2.** Forest plots of mean differences between groups of patients categorised by MRI status.
7 Mean differences (estimates) were significant between patients with history of stroke vs those with
8 SCI (left panel), patients with evidence of SCI vs patients with normal MRI (no evidence of SCI;
9 middle panel), and patients with no evidence of SCI and healthy controls (right panel).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Systematic review flow chart.
124x253mm (300 x 300 DPI)




Figure 2. Forest plots of mean differences between groups of patients categorised by MRI status. Mean differences (estimates) were significant between patients with history of stroke vs those with SCI (left panel), patients with evidence of SCI vs patients with normal MRI (no evidence of SCI; middle panel), and patients with no evidence of SCI and healthy controls (right panel).

Research and Reporting Methods | 2 June 2015

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

FREE

Brian Hutton, PhD, MSc; Georgia Salanti, PhD; Deborah M. Caldwell, PhD, MA, BA; Anna Chaimani, PhD; Christopher H. Schmid, PhD; Chris Cameron, MSc; John P.A. Ioannidis, MD, DSc; Sharon Straus, MD, MSc; Kristian Thorlund, PhD; Jeroen P. Jansen, PhD; Cynthia Mulrow, MD, MSc; Ferrán Catalá-López, PhD, MPH, PharmD; Peter C. Gøtzsche, MD, MSc; Kay Dickersin, PhD, MA; Isabelle Boutron, MD, PhD; Douglas G. Altman, DSc; and David Moher, PhD

Table. Checklist of Items to Include When Reporting a Systematic Review Involving a Network Meta-analysis

Section/Topic	Item # *	Checklist Item†	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review <i>incorporating a network meta-analysis (or related form of meta-analysis)</i> .	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: Background: main objectives Methods: data sources; study eligibility criteria, participants, and interventions; study appraisal; and <i>synthesis methods, such as network meta-analysis</i> . Results: number of studies and participants identified; summary estimates with corresponding confidence/credible intervals; <i>treatment rankings may also be discussed. Authors may choose to summarize pairwise comparisons against a chosen treatment included in their analyses for brevity.</i> Discussion/Conclusions: limitations; conclusions and implications of findings. Other: primary source of funding; systematic review registration number with registry name.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known, <i>including mention of why a network meta-analysis has been conducted</i> .	3
Objectives	4	Provide an explicit statement of questions being addressed, with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists and if and where it can be accessed (e.g., Web address); and, if available, provide registration information, including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. <i>Clearly describe eligible treatments included in the treatment network, and note whether any have been clustered or merged into the same node (with justification)</i> .	3
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	3
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	3
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	3
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	N/A
Geometry of the network	S1	Describe methods used to explore the geometry of the treatment network under study and potential biases related to it. This should include how the evidence base has been graphically summarized for presentation, and what characteristics were compiled and used to describe the evidence base to readers.	N/A
Risk of bias within individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	4
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means). <i>Also describe the use of additional summary measures assessed, such as treatment rankings and surface under the cumulative ranking curve (SUCRA) values, as well as modified approaches used to present summary findings from meta-analyses.</i>	4
Planned methods of analysis	14	Describe the methods of handling data and combining results of studies for each network meta-analysis. This should include, but not be limited to: <i>Handling of multigroup trials;</i> <i>Selection of variance structure;</i> <i>Selection of prior distributions in Bayesian analyses; and</i> <i>Assessment of model fit.</i>	4
Assessment of inconsistency	S2	Describe the statistical methods used to evaluate the agreement of direct and indirect evidence in the treatment network(s) studied. Describe efforts taken to address its presence when found.	4
Risk of bias across	15	Specify any assessment of Mac Keith Press the cumulative evidence (e.g., publication	8

studies		bias, selective reporting within studies).	
Additional analyses	16	Describe methods of additional analyses if done, indicating which were prespecified. This may include, but not be limited to, the following: Sensitivity or subgroup analyses; Meta-regression analyses; <i>Alternative formulations of the treatment network; and</i> <i>Use of alternative prior distributions for Bayesian analyses (if applicable).</i>	4
RESULTS†			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	4
Presentation of network structure	53	Provide a network graph of the included studies to enable visualization of the geometry of the treatment network.	N/A
Summary of network geometry	54	Provide a brief overview of characteristics of the treatment network. This may include commentary on the abundance of trials and randomized patients for the different interventions and pairwise comparisons in the network, gaps of evidence in the treatment network, and potential biases reflected by the network structure.	N/A
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	4
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment.	N/A
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: 1) simple summary data for each intervention group, and 2) effect estimates and confidence intervals. <i>Modified approaches may be needed to deal with information from larger networks.</i>	5
Synthesis of results	21	Present results of each meta-analysis done, including confidence/credible intervals. <i>In larger networks, authors may focus on comparisons versus a particular comparator (e.g., placebo or standard care), with full findings presented in an appendix. League tables and forest plots may be considered to summarize pairwise comparisons.</i> If additional summary measures were explored (such as treatment rankings), these should also be presented.	5
Exploration for inconsistency	55	Describe results from investigations of inconsistency. This may include such information as measures of model fit to compare consistency and inconsistency models, <i>P</i> values from statistical tests, or summary of inconsistency estimates from different parts of the treatment network.	5
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies for the evidence base being studied.	8
Results of additional analyses	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression analyses, <i>alternative network geometries studied, alternative choice of prior distributions for Bayesian analyses, and so forth).</i>	5
DISCUSSION			
Summary of evidence	24	Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, researchers, and policymakers).	6
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). <i>Comment on the validity of the assumptions, such as transitivity and consistency. Comment on any concerns regarding network geometry (e.g., avoidance of certain comparisons).</i>	8
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	7-8
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. This should also include information regarding whether funding has been received from manufacturers of treatments in the network and/or whether some of the authors are content experts with professional conflicts of interest that could affect use of treatments in the network.	N/A

* Boldface indicates new items to this checklist.

† Text in italics indicates wording specific to reporting of network meta-analyses that has been added to guidance from the PRISMA statement.

‡ Authors may wish to plan for use of appendices to present all relevant information in full detail for items in this section.

Copyright ©2015 American College of Physicians